Your browser doesn't support javascript.
loading
Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases.
Zimmer, Alexandra S; Steinberg, Seth M; Smart, Dee Dee; Gilbert, Mark R; Armstrong, Terri S; Burton, Eric; Houston, Nicole; Biassou, Nadia; Gril, Brunilde; Brastianos, Priscilla K; Carter, Scott; Lyden, David; Lipkowitz, Stanley; Steeg, Patricia S.
Afiliação
  • Zimmer AS; Women's Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20814, USA.
  • Steinberg SM; Biostatistics & Data Management Section, National Cancer Institute, NIH, Bethesda, MD 20814, USA.
  • Smart DD; Radiation Oncology Branch, National Cancer Institute, NIH, Bethesda, MD 20814, USA.
  • Gilbert MR; Neuro-Oncology Branch, National Cancer Institute, NIH, Bethesda, MD 20814, USA.
  • Armstrong TS; Neuro-Oncology Branch, National Cancer Institute, NIH, Bethesda, MD 20814, USA.
  • Burton E; Neuro-Oncology Branch, National Cancer Institute, NIH, Bethesda, MD 20814, USA.
  • Houston N; Women's Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20814, USA.
  • Biassou N; Neuro-Radiology, Clinical Center, NIH, Bethesda, MD 20814, USA.
  • Gril B; Women's Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20814, USA.
  • Brastianos PK; Central Nervous System Metastases Program, Massachusetts General Hospital/Harvard Cancer Center Boston, MA 02114, USA.
  • Carter S; Biostatistics and Computation Biology, Dana-Farber Cancer Institute, Boston, MA 02114, USA.
  • Lyden D; Pediatric Hematology Oncology, Weill Cornell Medicine, New York, NY 10065, USA.
  • Lipkowitz S; Women's Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20814, USA.
  • Steeg PS; Women's Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20814, USA.
Future Oncol ; 16(14): 899-909, 2020 May.
Article em En | MEDLINE | ID: mdl-32270710
Brain metastases occur in up to 25-55% of patients with metastatic HER2-positive breast cancer. Standard treatment has high rates of recurrence or progression, limiting survival and quality of life in most patients. Temozolomide (TMZ) is known to penetrate the blood-brain barrier and is US FDA approved for treatment of glioblastoma. Our group has demonstrated that low doses of TMZ administered in a prophylactic, metronomic fashion can significantly prevent development of brain metastases in murine models of breast cancer. Based on these findings, we initiated a secondary-prevention clinical trial with oral TMZ given to HER2-positive breast cancer patients with brain metastases after recent local treatment in combination with T-DM1 for systemic control of disease. Primary end point is freedom from new brain metastases at 1 year. (NCT03190967).
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Neoplasias da Mama / Telomerase / Antineoplásicos Alquilantes / Temozolomida Tipo de estudo: Clinical_trials / Prognostic_studies Idioma: En Revista: Future Oncol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Neoplasias da Mama / Telomerase / Antineoplásicos Alquilantes / Temozolomida Tipo de estudo: Clinical_trials / Prognostic_studies Idioma: En Revista: Future Oncol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos